Advertisement

The Influence of 5-Lipoxygenase on Alzheimer’s Disease-Related Tau Pathology: In Vivo and In Vitro Evidence

      Background

      Intracellular deposition of tau protein is a hallmark lesion of Alzheimer’s disease. Although it is known this event is secondary to excessive tau phosphorylation, the mechanisms involved remain unknown. We previously reported that the enzyme 5-Lipoxygenase (5LO) acts as a modulator of Aβ peptides formation in vivo, and here we investigate its influence on tau protein.

      Methods

      Tg2576 mice overexpressing neuronal 5LO were generated and its contribution to endogenous tau levels and metabolism investigated.

      Results

      Although no differences were noted in the levels of total tau for both groups, compared with controls, Tg2576 mice overexpressing 5LO had a significant increase in the phosphorylation state of tau at S396 and S396/S404, as recognized by the antibodies PHF-13 and PHF-1, respectively. By contrast, no phosphorylation changes were observed in other tau epitopes. This increase was associated with a significant elevation in cyclin dependent kinase-5 but not other kinases that have been involved in tau phosphorylation. Additionally, mice overexpressing 5LO had biochemical evidence of altered synaptic integrity because they manifested a reduction in PSD-95, synaptophysin and MAP2.

      Conclusions

      This study demonstrates a new role for 5LO in regulating endogenous tau metabolism in the central nervous system and supports the hypothesis that its pharmacologic inhibition could be beneficial for Alzheimer’s disease-related tau neuropathology.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Hernandez F.
        • Avila J.
        Tauopathies.
        Cell Mol Life Sci. 2007; 64: 2219-2233
        • Geschwind D.H.
        Tau phosphorylation, tangles, and neurodegeneration: the chicken or the egg?.
        Neuron. 2003; 40: 457-460
        • Iqbal K.
        • Liu F.
        • Gong C.X.
        • Grundke-Iqbal I.
        Tau in Alzheimer disease and related tauopathies.
        Curr Alz Res. 2010; 7: 656-664
        • Mederios R.
        • Baglietto-Vargas D.
        • Laferla F.
        The role of tau in Alzheimer’s disease and related disorders.
        CNS Neurosci Ther. 2011; 17: 514-524
        • Ishizawa K.
        • Dickson D.W.
        Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration.
        J Neuropathol Exp Neurol. 2001; 60: 647-657
        • Kitazawa M.
        • Oddo S.
        • Yamasaki T.R.
        • Green K.N.
        • Laferla F.
        Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5 mediated pathways in a transgenic model of Alzheimer’s disease.
        J Neurosci. 2005; 25: 8843-8853
        • Bhaskar K.
        • Konerth M.
        • Kokiko-Cochran O.
        • Cardona A.
        • Ransohoff R.
        • Lamb B.
        Regulation of tau pathology by microglial fractalkine receptor.
        Neuron. 2010; 68: 19-31
        • Yoshima Y.
        • Higuchi M.
        • Zhang B.
        • Huang S.M.
        • Iwata N.
        • Saido T.C.
        • et al.
        Synapse loss and microglial activation precede tangle in a P301S tauopathy mouse model.
        Neuron. 2007; 53: 337-351
        • Chinnici C.
        • Yao Y.
        • Praticò D.
        The 5-Lipoxygenase enzymatic pathways in the mouse brain: Young versus old.
        Neurobiol Aging. 2007; 28: 1457-1462
        • Ikonomovic M.D.
        • Abrahamson E.E.
        • Uz T.
        • Manev H.
        • Dekosky S.T.
        Increased 5-lipoxygenase immunoreactivity in hippocampus of patients with Alzheimer’s disease.
        J Histochem Cytochem. 2008; 56: 1065-1073
        • Firuzi O.
        • Zhou J.
        • Chinnici C.M.
        • Wisnieski T.
        • Praticò D.
        5-Lipoxygenase gene disruption reduces amyloid-{beta} pathology in a mouse model of Alzheimer’s disease.
        FASEB J. 2008; 22: 1169-1178
        • Chu J.
        • Pratico D.
        Pharmacologic blockade of 5–Lipoxygenase improves the amyloidotic phenotype of an AD transgenic mouse model: Involvement of γ-secretase.
        Am J Pathol. 2011; 178: 1762-1769
        • Chu J.
        • Giannopoulos P.J.
        • Ceballos-Diaz C.
        • Golde T.
        • Pratico D.
        Adeno-associated virus-mediated brain delivery of 5-Lipoxygenase modulates the AD-like phenotype of APP mice.
        Mol Neurodegen. 2012; 7: 1
        • Levites Y.
        • Jansen K.
        • Smithson L.A.
        • Dakin R.
        • Holloway V.M.
        • Das P.
        • Golde T.E.
        Intracranial adeno-associated virus mediated delivery of antipan amylodi Aβ, amyloid β40, and amyloid β42 single-chain variable fragments attenuates plaque pathology in amyloid precursor protein mice.
        J Neurosci. 2006; 26: 11923-11928
        • Kim J.
        • Miller V.M.
        • Levites Y.
        • Jansen West K.
        • Zwiziski G.W.
        • Moore B.D.
        • et al.
        BRI2(ITM2b) inhibits Abeta deposition in vivo.
        J Neurosci. 2008; 28: 6030-6036
        • Andorfer C.
        • Kress Y.
        • Espinoza M.
        • de Silva R.
        • Tucker K.L.
        • Barde Y.
        • et al.
        Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms.
        J Neurochem. 2003; 86: 582-590
        • Joshi Y.
        • Chu J.
        • Pratico D.
        Stress hormone leads to memory deficits and altered tau phosphorylation in a mouse model of Alzheimer’s disease.
        J Alz Dis. 2012; 31: 167-176
        • Iwakiri M.
        • Mizukami K.
        • Ikonomovic M.
        • Ishikawa M.
        • Abrahamson E.
        • Dekosky S.
        • Asada T.
        An immunohistochemical study of GABA receptor gamma subunits in Alzheimer’s disease hippocampus: Relationship to neurofibrillary tangle progression.
        Neuropathology. 2009; 29: 263-269
        • Gong C.X.
        • Iqbal K.
        Hyperphosphorylation of microtubule-associated protein tau: A promising therapeutic target for Alzheimer disease.
        Curr Med Chem. 2008; 15: 2321-2328
        • Sampson A.P.
        Five lipoxygenase activating protein inhibitors for the treatment of inflammatory disease.
        Curr Opin Investig Drugs. 2009; 10: 1163-1172
        • Qu T.
        • Manev R.
        • Manev H.
        5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer’s disease.
        J Neuropsychiatry Clin Neurosci. 2001; 13: 304-305
        • Chu J.
        • Giannopoulos P.J.
        • Ceballos-Diaz C.
        • Golde T.
        • Pratico D.
        5-Lipoxygenase gene transfer worsens memory, amyloid and tau brain pathologies in a mouse model of Alzheimer disease.
        Ann Neurol. 2012; 72: 442-454
        • Martin L.
        • Latypova X.
        • Terro F.
        Post-translational modifications of tau protein: Implications for Alzheimer’s disease.
        Neurochem Int. 2011; 58: 458-471
        • Atzori C.
        • Ghetti B.
        • Piva R.
        • Srinivasan A.N.
        • Zolo P.
        • Delisle M.B.
        • et al.
        Activation of JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis.
        J Neuropathol Exp Neurol. 2001; 60: 1190-1197
        • Savage M.J.
        • Lin Y.G.
        • Ciallela J.R.
        • Flood D.G.
        • Scott R.W.
        Activation of c-Jun N-terminal kinase and p38 in an Alzheimer’s disease model is associated with amyloid deposition.
        J Neurosci. 2002; 22: 3376-3385
        • Sun W.
        • Qureshi H.Y.
        • Cafferty P.W.
        • Sobue K.
        • Agarwal-Mawal A.
        • Neufield K.D.
        • Paudel H.K.
        Glycogen synthase kinase-beta is complexed with tau protein in brain microtubules.
        J Biol Chem. 2002; 277: 11933-11940
        • Liu S.J.
        • Zhang A.H.
        • Li H.L.
        • Wang Q.
        • Deng H.M.
        • Netzer W.J.
        • et al.
        Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory.
        J Neurochem. 2003; 87: 1333-1344
        • Humbert S.
        • Dhavan R.
        • Tsai L.
        p39 activates cdk5 in neurons, and is associated with the actin cytoskeleton.
        J Cell Sci. 2000; 113: 975-983
        • Lee M.S.
        • Tsai L.H.
        Cdk5: One of the links between senile plaques and neurofibrillary tangles?.
        J Alz Dis. 2003; 5: 127-137
        • Hsiao Y.H.
        • Kuo J.R.
        • Chen S.H.
        • Gean P.W.
        Amelioration of social isolation-triggered onset of early Alzheimer’s disease-related cognitive deficit by N-acetylcysteine in a transgenic mouse model.
        Neurobiol Dis. 2012; 45: 1111-1120
        • Imbesi M.
        • Zavoreo I.
        • Uz T.
        • Sharma R.P.
        • Dimitrijevic N.
        • Manev H.
        • Manev R.
        5-Lipoxygenase inhibitor MK-886 increases GluR1 phosphorylation in neuronal cultures in vitro and in the mouse cortex in vivo.
        Brain Res. 2007; 1147: 148-153